Lundbeck Inc. Halts Sales of Leukemia Drug Over Supply Problems

Published: Sep 17, 2012

H. Lundbeck A/S (LUN.KO) plans to stop selling a leukemia treatment because of manufacturing and supply difficulties. Denmark-based Lundbeck "is no longer in a position to guarantee a future supply" of the drug Elspar, Roger Keding, vice president of supply chain management, said in an Aug. 3 letter to U.S. health-care providers. "Lundbeck has concluded that continuing to manufacture and distribute Elspar is not a sustainable business going forward." The company plans to discontinue Elspar sales globally, and to stop selling Elspar in the U.S. effective Dec. 31; the date could change depending on remaining inventory.

Back to news